^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Triple Negative Breast Cancer
    Drug:Rubraca (rucaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Peritoneal Cancer)
    New
    Excerpt:
    RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated...for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

    Excerpt:
    ...- Solid tumor, advanced or metastatic, progressed on standard treatment participants in Arm B must have either triple negative breast cancer OR urothelial carcinoma OR ovarian cancer OR have a solid tumor with a deleterious mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D...
    Trial ID:
    SEASTAR
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)

    Excerpt:
    ......
    Trial ID:
    2014-003319-12
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    NPJ Breast Cancer
    Title:

    Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

    Published date:
    03/22/2021
    Excerpt:
    CONTRADICTING EVIDENCE: Patients with TNBC or deleterious BRCA mutation (TNBC/BRCAmut)...In the high-risk post preoperative TNBC/BRCAmut setting, the addition of low-dose rucaparib did not improve 2-year DFS or increase the toxicity of cisplatin...
    Secondary therapy:
    cisplatin
    DOI:
    10.1038/s41523-021-00240-w
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 3026: Evaluation of brain pharmacokinetics (PK) and tumor growth inhibition of PARP inhibitors in mouse xenograft models using semi-mechanistic PK/pharmacodynamic (PD) modeling

    Published date:
    05/15/2020
    Excerpt:
    We evaluated the brain penetration of PARP inhibitors in mice and the anti-tumor effects...in orthotopic and intracranial BRCA1-mutant triple-negative breast cancer (TNBC)...rucaparib and niraparib demonstrated antitumor efficacy in a BRCA1-mutant, intracranial, TNBC mouse model.
    DOI:
    10.1158/1538-7445.AM2020-3026